Review of economic studies and budget impact analysis of ocriplasmin as a treatment of vitreomacular traction

García-Pérez, Lidia; Abreu-González, R.; Pérez-Ramos, Jeanette; García-Pérez, Sonia; Serrano‐Aguilar, Pedro

doi:10.1016/j.oftale.2016.04.023

Cited by 3 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Economic evaluations of treatment options for symptomatic vitreomacular adhesion (i.e., VMT) and macular holes have been published previously. These budget impact analyses of ocriplasmin injection suggested that it may be cost saving in Spain and the Canary Islands (though uncertainty was high) and cost additive in Ireland [41]. The uncertainty of results was attributed to uncertainty in, and model sensitivity to, the costs of ocriplasmin injection and vitrectomy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Yu¹,

Haller

Kaiser

et al. 2018

J. Comp. Eff. Res.

View full text Add to dashboard Cite

Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea R ). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials & methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complicationsrelated costs decreased.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A review of economic studies of ocriplasmin injection reported that ocriplasmin has been found to be a costeffective treatment for VMT patients without ERM in Canada, France and the UK compared with watchful waiting followed by vitrectomy as needed [41]. Results were less positive in unselected VMT populations with ERM.…”

Section: Discussionmentioning

confidence: 99%

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Yu¹,

Haller

Kaiser

et al. 2018

J. Comp. Eff. Res.

View full text Add to dashboard Cite

show abstract

“…Few costing studies have been reported in the treatment of symptomatic VMA. A budget-impact analysis in the USA and Spain concluded that ocriplasmin versus SOC offset some drug costs by reducing the number of vitrectomies [38] or resulted in cost savings over a 5-year period [46].…”

Section: Discussionmentioning

confidence: 99%

Cost–effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US

et al. 2020

View full text Add to dashboard Cite

Aim: Evaluate the cost–effectiveness of ocriplasmin in symptomatic vitreomacular adhesion (VMA) with or without full-thickness macular hole ≤400 μm versus standard of care. Methods: A state-transition model simulated a cohort through disease health states; assignment of utilities to health states reflected the distribution of visual acuity. Efficacy of ocriplasmin was derived from logistic regression models using Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole trial data. Model inputs were extracted from Phase III trials and published literature. The analysis was conducted from a US Medicare perspective. Results: Lifetime incremental cost–effectiveness ratio was US$4887 per quality-adjusted life year gained in the total population, US$4255 and US$10,167 in VMA subgroups without and with full-thickness macular hole, respectively. Conclusion: Ocriplasmin was cost effective compared with standard of care in symptomatic VMA.

show abstract

“…5 However, ocriplasmin might be cost-effective in selected patients. 6 The aim of this study is to estimate long-term results after vitrectomy with internal limiting membrane (ILM) peeling in VMT, as well as to estimate factors influencing the final visual outcome.…”

Section: Introductionmentioning

confidence: 99%

Vitrectomy in the Management of Vitreomacular Traction Syndrome

Michalewska¹,

Nawrocki²

2018

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

To estimate long-term results after vitrectomy with internal limiting membrane peeling in vitreomacular traction syndrome (VMTS), as well as to estimate factors influencing final visual outcome. Methods: Medical records of all patients who underwent pars plana vitrectomy for idiopathic VMTS from 2007 through 2015 were assessed. Spectral domain optical coherence tomography was performed preoperatively and at least 6 months after surgery. The mean horizontal and vertical diameters of the vitreomacular traction (VMT) were measured. The area of vitreomacular attachment was calculated. Results: Twenty-four eyes of 22 patients (mean age, 74 years) were included in this study. Mean visual acuity improved significantly from 0.26 Snellen (0.69 logMAR) to 0.39 Snellen (0.43 logMAR) in the mean of 29 months after surgery (7-90 months; median, 25 months; P ¼ .02, paired t test). Visual acuity improved in 18 eyes, remained unchanged in 2 cases, and decreased postoperatively in 4 eyes. Multiple regression analysis did not reveal any factors significant for determining final visual acuity. However, when regrouping the patients according to the International Vitreomacular Traction Study Group, we observed that final visual acuities were statistically significantly better in eyes with focal vitreous detachment compared to broad vitreous detachment (P ¼ .04). Conclusions: Despite the fact that VMT is a 3-dimensional disease, the calculated area of attachment was not greater than the vertical diameter of attachment. According to the current study, the classification of VMT proposed by the VMT Study Group might be an important tool in predicting the final visual outcome after vitrectomy.

show abstract

Review of economic studies and budget impact analysis of ocriplasmin as a treatment of vitreomacular traction

Cited by 3 publications

References 11 publications

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Cost–effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US

Vitrectomy in the Management of Vitreomacular Traction Syndrome

Contact Info

Product

Resources

About